Abstract:To achieve targeted, truly systemic therapeutic gene delivery to tumors, we exploited the observation that infection by a retrovirus proceeds initially through a non-specific adsorption stage prior to envelope-receptor recognition/internalization. Antigen specific, primary murine OT-1 T cells can be incubated in vitro with retroviral stocks which adhere to the cell surface. In vitro, virus can be handed off to target cells upon co-culture with the T cells, dependent upon cell contact, envelope/receptor interactions and local heparanase expression as provided by T cell activation upon encounter of antigen (ovalbumin) by the OT-1 T cells. Retroviral particles, pre-adsorbed to the surface of OT-1 T cells in vitro, were available for hand off in vivo to B16ova tumors distant from the site of T cell injection at high enough concentrations for therapeutic levels of gene transfer to occur. We have now delivered a variety of therapeutic genes to tumors, including HSVtk, IL-12 and the chemokine CCL-21. Pre- adsorption of vectors encoding each of these genes has led to therapeutic benefits in terms of direct local cell killing (HSVtk in combination with lymphodepletion), generation of potent immunizing activity (IL-12) and significant enhancement of the efficacy of subsequent doses of adoptively transferred, unmodified T cells (CCL-21). We have also characterized a second pathway by which viral particles expressing no envelope (BALD particles) can be handed off from T cells dependent upon T cell activation. Release of viral particles from the T cell surface coincides with the penetration of perforin-containing cytotoxic vesicles from the antigen activated T cells. The endosomolytic properties of perforin promote release of these viral particles from the endosome and, in situations where direct T cell killing does not occur, the virus goes onto to generate a productive infection. Thus, T cell mediated delivery of MLV core particles can be used to deliver therapeutic retroviral vectors in vivo using targeting at the level of T cell activation, thereby dispensing with the need to target viral envelopes. We have also investigated the possibilities of using antigen specific T cells to deliver replication competent viruses to tumors both in vitro and in vivo. In particular, we have demonstrated that replication competent Vesicular Stomatitis virus expressing GFP can be used to load OT-1 T cells. The virus infects these T cells only at very low levels and does not kill them. However, the T cells produce VSV particles at appreciable levels 48-72 hours post loading suggesting that they may be able to carry the viruses to tumors in vivo and lead to productive infection following intratumoral T cell accumulation. Therefore, the protection, concentration, and targeted delivery of viruses by T cell carriers offers great potential for the delivery of vector stocks into the circulation of patients. By careful selection of the virus, and therapeutic gene that is used, significant synergy can be achieved over the use of virotherapy, or adoptive T cell therapy, alone.

Strategies for the rapid construction of conditionally-replicating HSV-1 vectors expressing foreign genes as anticancer therapeutic agents

Exploiting non-permissive CHO cells as a rapid and efficient method for recombinant HSV-1 isolation

High-efficiency nonhomologous insertion of a foreign gene into the herpes simplex virus genome

Safety of non-replicative and oncolytic replication-selective HSV vectors

Non-replicative herpes simplex virus genomic and amplicon vectors for gene therapy - an update

Efficient Strategy for Synthesizing Vector-Free and Oncolytic Herpes Simplex Type 1 Viruses

Therapeutic Efficiency and Safety of a Second-Generation Replication-Conditional HSV1 Vector for Brain Tumor Gene Therapy

Replication-Competent Controlled Herpes Simplex Virus

Cellular Antisilencing Elements Support Transgene Expression from Herpes Simplex Virus Vectors in the Absence of Immediate Early Gene Expression

Genetic engineering of herpes simplex virus and vector genomes carrying loxP sites in cells expressing Cre recombinase

Molecular genetics of herpesviruses: a recombinant technology approach.

HSV trafficking and development of gene therapy vectors with applications in the nervous system

Construction and Identification of Recombinant Vectors Carrying Herpes Simplex Virus Thymidine Kinase and Cytokine Genes Expressed in Gastric Carcinoma Cell Line SGC7901

High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional ICP27 and ICP34.5

Efficient site-specific integration of large transgenes by an enhanced herpes simplex virus/adeno-associated virus hybrid amplicon vector

812. Cellular Delivery of Gene Therapy Vectors

Increasing the Efficiency of CRISPR/Cas9-mediated Precise Genome Editing of HSV-1 Virus in Human Cells

Construction of an IL12 and CXCL11 armed oncolytic herpes simplex virus using the CRISPR/Cas9 system for colon cancer treatment

Construction and characterization of a synthesized herpes simplex virus H129-Syn-G2

Novel Vector Construction Based on Alternative Adenovirus Types Via Homologous Recombination

Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability